Conclusions: We successfully developed and validated a risk stratification system that integrates baseline clinical characteristics (diabetes, cTnI levels), ANS parameters (nLF/nHF ratio, DC), and coronary physiological assessment (post-PCI QFR). This evidence concerns the gene TNNI3 and diabetes mellitus.